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MaOBJECTIVES The study sought to compare the relative discrimination of various cardiopulmonary exercise testing
(CPX) variables between cardiac and respiratory disease.
BACKGROUND CPX testing is used in many cardiorespiratory diseases. However, discrimination of cardiac and respi-
ratory dysfunction can be problematic. Anaerobic threshold (AT) and oxygen-uptake to work-rate relationship (VO2/WR
slope) have been proposed as diagnostic of cardiac dysfunction, but multiple variables have not been compared.
METHODS A total of 73 patients with chronic obstructive pulmonary disease (COPD) (n ¼ 25), heart failure with reduced
ejection fraction (HFrEF) (n ¼ 40), or combined COPD and HFrEF (n ¼ 8) were recruited and underwent CPX testing on a
bicycle ergometer. Following a familiarization test, each patient underwent a personalized second test aiming for
maximal exercise after w10 min. Measurements from this test were used to calculate area under the receiver-operator
characteristic curve (AUC).
RESULTS Peak VO2was similar between the 2 principal groups (COPD 17.1 4.6ml/min/kg; HFrEF 16.4 3.6ml/min/kg).
Breathing reserve (AUC: 0.91) and percent predicted oxygen uptake efﬁciency slope (OUES) (AUC: 0.87) had the greatest
ability to discriminate between COPD and HFrEF. VO2/WR slope performed signiﬁcantly worse (AUC: 0.68). VO2 at the AT
did not discriminate (AUC for AT as percent predicted peak VO2: 0.56). OUES and breathing reserve remained strong
discriminators when compared with an external cohort of healthy matched controls, and were comparable to B-type
natriuretic peptide.
CONCLUSIONS Breathing reserve and OUES discriminate heart failure from COPD. Despite it being considered an
important determinant of cardiac dysfunction, the AT could not discriminate these typical clinical populations while the
VO2/WR slope showed poor to moderate discriminant ability. (Identifying an Ideal Cardiopulmonary Exercise Test
Parameter [PVA]; NCT01162083) (J Am Coll Cardiol HF 2016;4:252–61) © 2016 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://
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253AB BR E V I A T I O N S
AND ACRONYM S
AT = anaerobic threshold
AUC = area under the receiver-
operator characteristic curve
BNP = B-type natriuretic
peptide
BR = breathing reserve
COPD = chronic obstructive
pulmonary disease
CPX = cardiopulmonary
exercise testing
MVV = maximal voluntary
ventilation
OUES = oxygen uptake
efﬁciency slope
ROC = receiver-operating
characteristic
VO2 = oxygen uptakeC ardiopulmonary exercise testing (CPX) isrecommended for the identiﬁcation of thekey-limiting organ in a patient presenting
with exercise intolerance or dyspnea (1). Most diag-
nostic algorithms are similar (2–5): peak oxygen up-
take (VO2) is used to determine the extent of
limitation and the combination of anaerobic
threshold (AT) and breathing reserve (BR) is used to
determine cause. A BR cutoff of 30% and an AT cutoff
of 40% of predicted peak VO2 have typically been
used to discriminate between respiratory and cardiac
limitation respectively. However, it may be difﬁcult
to establish etiology if abnormalities in cardiac and
respiratory function coexist (6). BR, measured at
peak (7) or AT (8), discriminates patients with known
respiratory disease from healthy adults and those
with heart disease, in small, selective studies. These
results have not been replicated in independent sam-
ples, these studies employed small sample sizes and
participants were highly selected.SEE PAGE 262It is also unclear how best to assess change in sta-
tus using serial measurements of a single patient
when pulmonary and cardiac pathologies coexist,
which is not uncommon. In 1 study of chronic heart
failure (CHF) patients 40% had spirometry suggestive
of chronic obstructive pulmonary disease (COPD) (9).
Another reported that CHF was present in w20% of
people with COPD (10).
This study aimed to establish which CPX variables
showed the best ability to discriminate between res-
piratory and cardiac limitation in a prospective cohort
of patients with COPD, heart failure with reduced
ejection fraction (HFrEF), and coexisting COPD and
HFrEF.
METHODS
RECRUITMENT. Patients with a diagnosis of HFrEF or
COPD were eligible for the study. HFrEF patients
were prospectively recruited from a heart failure
clinic. They must have been symptomatic at some
point in the past. Sequential symptomatic COPD
patients were recruited from an outpatient clinic.
Four patients with COPD found to have ventri-
cular dysfunction, and 4 patients with HFrEF with
obstructive spirometry and COPD features (smoking
history, typical computed tomography ﬁndings,
sputum production) were subsequently reclassiﬁed
into a mixed group.
Exclusion criteria included: inability to perform
an exercise test, signiﬁcant renal impairment (esti-
mated glomerular ﬁltration rate <30 ml/min/1.73 m2),angina, recent cardiorespiratory decompen-
sation, anemia, morbid obesity, and standard
contraindications to exercise testing. All pa-
tients’ care was managed by Imperial College
Healthcare NHS Trust, or Royal Brompton
and Hareﬁeld Hospital NHS Trust (London,
England). The study conformed to the prin-
ciples of the Declaration of Helsinki and was
approved by the Imperial College Healthcare
NHS Trust Research Ethics Committee. Par-
ticipants provided written informed consent.
Healthy controls were obtained from the
SHIP (Study of Health In Pomerania) study,
from which normal equations have been
derived for a number of CPX variables. Study
methodology has been described elsewhere
(11). Brieﬂy this population study recruited
7,008 adults with 292 persons of each sex in
each 12 5-year age strata. The ﬁnal sample
comprised 3,300 subjects (1,589 males) 25 to 85 years
of age. Of those, 1,708 individuals (834 males) vol-
unteered for an incremental cycle exercise test from
which the healthy controls were drawn. Matching was
performed on a 2:1 ratio for each case; matched to
gender, age within 5 years, and same body mass index
category (underweight, healthy weight, overweight,
obese).
LUNG FUNCTION AND CPX TESTING. All HFrEF and
COPD participants underwent full lung function
testing using a Spiro Air (Medisoft, Sorinnes, Belgium),
and exercise testing on an ergoselect 100 ergometer
(Ergoline GmbH, Bitz, Baden-Württemberg, Germany)
in an air-conditioned room. Twelve-hour absten-
tion from caffeinated products was encouraged. CPX
was performed using COSMED Quark CPX System
(COSMED S.r.l., Rome, Italy), calibrated before each
test. Three minutes of unloaded cycling preceded a 10
W/min ramp protocol exercising to exhaustion, with
breath-by-breath gas exchange data. Blood pressure
was recorded every 3 min using a manual sphygmo-
manometer. Patients underwent a second CPX at
least 2 h after this familiarization test. This was similar
to the ﬁrst test, with 3 min unloaded, then incremental
exercise butwith a ramp protocol of 6, 8, 10, 12, 15, or 20
W/min depending on the results of the initial test, to
elicit exhaustion between 8 and 10 min of incremental
exercise. If 6 incremental minutes were achieved on
the familiarization test a 6 W second test protocol was
deemed suitable; 20 min on the familiarization test led
to a 20 W protocol, and so forth.
CALCULATION OF CPX MEASURES. Full details of
calculations and abbreviations are provided in the
Online Appendix. Brieﬂy all peak measures used the
TABLE 1 Patient Cha
Age, yrs
Male
Weight, kg
Height, cm
Body mass index, kg/m
Diabetes
Current smokers
Hypertensive
Beta-blocker use
ACEI/ATII-R use
Hb, g/dl
eGFR, ml/min/1.73 m2
BNP, pg/ml
FVC, l
FVC, % predicted
FEV1, l
FEV1 (% predicted)
FEV1:FVC ratio, %
KCO, min
–1
Ramp protocol, W/min
LVEDV, cm3
LVESV, cm3
LVEF, %
LVFS (%)
LA volume, cm3
TAPSE, mm
RV S’-wave, cm/s
Values are mean SD, n (%
healthy controls) by analys
ACEI ¼ angotensin-conv
natriuretic peptide; COPD ¼
FEV1 ¼ forced expiration in
fraction; LA ¼ left atrial; LV
LVESV ¼ left ventricular
ventricular; TAPSE ¼ tricus
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254highest 20-s average. The AT was identiﬁed using
unaveraged breath-by-breath data using the V-slope
method (12), and corroborated using other plots. VO2
at AT, minute ventilation:carbon dioxide (VE/VCO2)
ratio at AT, and end-tidal CO2 (PETCO2) (mm Hg) were
taken at this time point. The oxygen uptake efﬁciency
slope (OUES) was calculated as the slope of the
regression line between log10 minute ventilation
(x-axis) and VO2 (y-axis). The VE/VCO2 slope was
calculated using data until the ventilatory compen-
sation point  slope 1, and using all exercise data,
including exercise after ventilatory compensation
point  slope 2. Maximal voluntary ventilation (MVV)
was calculated as: 40 $ forced expiratory volume in 1 s
(FEV1). Predicted values for peak VO2 and OUES were
generated from the SHIP study (13,14). All otherracteristics
p Value Between
Groups COPD HFrEF Healthy Adults
0.85 66.3  9.9 66.7  11.0 64.9  9.8
0.01 19 (65.6) 39 (88.6) 106 (79)
0.001 70.7  16.0 82.6  15.3 81.0  15.7
0.90 166.4  7.5 171.8  9.6 170.6  7.8
2 0.89 25.4  4.8 28.0  4.2 27.7  4.4
0.07 1 (3) 8 (18) 0 (0)
0.55 5 (17) 7 (16) 20 (15)
0.06 15 (52) 20 (46) 49 (37)
<0.001 1 (3) 38 (86) 23 (17)
<0.001 5 (17) 40 (91) Not recorded
0.01 14.4  1.12 13.8  1.35 15.4  1.33
0.05 83.0  19.2 69.9  17.9 Not recorded
<0.001 32.5 (14–50) 122 (85–286) Not recorded
0.01 2.75 (2.29–
3.06)
3.57 (2.96–4.29) 3.80 (3.01,4.29)
0.01 88.6  24.9 99.3  18.7 99.0  16.1
<0.001 1.28  0.48 2.50  0.74 3.08  0.78
<0.001 51.9  20.3 88.5  21.4 102.3  15.4
<0.001 43.3 (35.8–55.9) 71.0 (62.7–76.4) 82.5
(78.0,86.0)
0.007 0.94  0.38 1.15  0.30 1.41  0.34
0.65 10.1  2.8 11.3  2.9 Not recorded
<0.001 75  33 161  53 Not recorded
<0.001 27.5 (19.4–36.7) 99.8 (68.3–145.3) Not recorded
<0.001 58.3  10.5 35.3  9.4 Not recorded
<0.001 27.9  6.4 16.2  6.9 Not recorded
<0.001 42.6 (33.3–61.4) 74.6 (56.4–
104.4)
Not recorded
0.004 21  4 19  4 Not recorded
<0.001 12.3  3.3 10.3  2.4 Not recorded
), or median (interquartile range). The p values are between disease groups (excluding
is of variance for continuous variables and chi-square analysis for categorical variables.
erting enzyme inhibitor; ATII-R ¼ angiotensin II receptor blocker; BNP ¼ B-type
chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate;
1 second; FVC ¼ forced vital capacity; HFrEF ¼ heart failure with reduced ejection
EDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction;
end-systolic volume; LVFS ¼ left ventricular fractional shortening; RV ¼ right
pid annular plane systolic excursion.calculations were performed using standard methods.
The AT was described as a percentage of predicted
peak VO2.
A number of CPX variables were never calculated
in the SHIP cohort, and so these variables were only
analyzed for the 2 disease groups.
OTHER MEASURES. Echocardiography was per-
formed using an IE33 ultrasound system (Philips,
Amsterdam, the Netherlands) and B-type natriuretic
peptide (BNP) was measured.
STATISTICAL ANALYSIS. Statistical analysis was
performed using Stata version 11.1 for Windows (Sta-
taCorp LP, College Station, Texas). Normality of
continuous variables was assessed using the Shapiro-
Wilk test. Skewed variables were log transformed or
nonparametric analyses used. A one-way analysis of
variance was used to compare differences; for non-
normally distributed variables a Kruskal-Wallis test
was used. Categorical variables were compared with a
chi-square test. Associations between FEV1, percent
predicted FEV1, and the transfer coefﬁcient corrected
for Hb (KCO(Hb)) and CPX variables were assessed
using a multivariate model including age, gender, and
weight as pre-speciﬁed covariates.
The ability of each variable to discriminate between
the 3 groups was assessed using the area under the
receiver-operator characteristic (ROC) curve (AUC)
with their 95% conﬁdence interval. AUC $0.8, 0.7 to
0.8, and <0.7 were considered good, moderate, and
poor respectively. Variables with good AUC were
compared using the Stata roccomp command while all
values were compared using the rocgold command
with a Bonferroni correction. The primary analysis was
a comparison of AUC in HFrEF against COPD patients
(excluding mixed disease). Secondary analyses were
both groups against the healthy matched controls, and
the 2 disease groups including the mixed disease pa-
tients by original diagnosis. The ROC was arranged to
give values $0.50. Variables requiring the AT to be
achieved were initially only assessed in the patients
who achieved the AT. To correct for the reduced
number of patients achieving AT further analysis was
done with peak VO2 substituting for VO2 at AT in those
not achieving AT. For net reclassiﬁcation improve-
ment and integrated discrimination improvement we
compared accepted cutoffs (AT <40% predicted peak
VO2) to identify HFrEF with the optimal variable
identiﬁed from ROC curve analysis. Patients were
scoredþ1 (patient correctly reclassiﬁed toHFrEF), zero
(did not change groups), or –1 (patient incorrectly
reclassiﬁed as not having HFrEF).
A p value of <0.05 was considered signiﬁcant
throughout.
TABLE 2 CPX Results for a Number of Principal Variables Divided Into Disease
Categories; COPD and HFrEF
COPD
(n ¼ 25)
HFrEF
(n ¼ 40)
Healthy Adults
(n ¼ 134)
Peak VO2, ml/min*† 1,356  73 1,299  56 1,937  31
Peak VO2, ml/min/kg*† 16.7  0.9 16.5  0.7 24.4  0.4
Peak VO2, % predicted*† 69.9  3.4 70.6  2.6 101.0  1.4
AT, ml/min*† 983  60 941  39 1,157  22
AT, % of predicted peak VO2*† 52.4  2.9 51.2  1.8 60.3  1.0
OUES‡ 2.11  0.09 1.50  0.07 2.27  0.04
OUES/kg†§ 27.0  1.2 19.1  0.9 28.6  0.5
OUES, % predicted†§ 105.6  4.1 72.6  3.1 102.5  1.7
OUEP§ 30.5  1.0 33.5  0.8 Not recorded
O2 pulse, ml/beat‡ 10.7  0.5 12.1  0.4 13.8  0.2
O2 pulse, % predicted*† 77.9  3.2 82.6  2.5 100.0  1.3
VE/VCO2 slope 1*† 33.6  1.1 36.0  0.8 26.5  0.5
VE/VCO2 slope 2 34.1  1.9 38.6  1.5 Not recorded
VE/VCO2 ratio nadir 35.2  1.2 33.9  0.9 Not recorded
VE/VCO2 ratio at AT*† 38.7  1.2 35.7  0.8 29.0  0.4
RER at peak§ 0.99  0.02 1.11  0.02 Not recorded
PETCO2 at AT, mm Hg*† 34.8  1.0 35.1  0.7 38.7  0.4
HR at peak, beats/min‡ 126  4 115  3 141  2
DP, mm Hg beats/min§ 23,566  1205 17,630  907 28,871  493
Circ power, mm Hg l/min*† 259.3  20.7 196.6  15.6 398.9  8.5
Peak O2 saturations, %§ 94  1 98  1 Not recorded
BR at AT, %§ 49.8  2.8 69.5  1.8 Not recorded
BR, %*§ 9.3  3.0 42.6  2.3 46.8  1.2
VO2/WR slope†§ 9.8  0.3 8.7  0.2 9.7  0.1
HR/VO2 slope* 0.043  0.003 0.045  0.002 0.042  0.001
Peak work rate, W‡ 85  6 93  5 145  3
Duration, mins:s 10:32  0:19 11:05  0:15 N/A
Values are mean  SE. The values represent adjusted means based on the analysis of variance model including
age, gender, and weight. *Signiﬁcant difference between COPD and healthy adults. †Signiﬁcant difference be-
tween HFrEF and healthy adults. ‡Signiﬁcant differences between all groups. §Signiﬁcant difference between
COPD and HFrEF.
AT ¼ anaerobic threshold; BR ¼ breathing reserve; CPX ¼ cardiopulmonary exercise testing; DP ¼ double
product; HR ¼ heart rate; OUES ¼ oxygen uptake efﬁciency slope; PETCO2 ¼ end-tidal CO2; RER ¼ respiratory
exchange ratio; VE ¼ minute ventilation; VO2 ¼ oxygen uptake; VO2/WR slope ¼ oxygen-uptake to work-rate
relationship; other abbreviations as in Table 1.
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255RESULTS
PATIENT RECRUITMENT AND CHARACTERISTICS. A
total of 73 patients (58 male) were recruited; 44 had
HFrEF, 15 were awaiting CRT, 16 had previously un-
dergone CRT, and 29 had COPD. Patient characteris-
tics of the groups are shown in Table 1. Disease groups
did not signiﬁcantly differ by age, but did by gender
(p ¼ 0.01) and weight (p ¼ 0.001), and further char-
acteristics were corrected for age, gender, and
weight. Most HFrEF patients were symptomatic
(5 NYHA functional class I, 30 functional class II, 9
functional class III).
Within the COPD category, 2 patients were cate-
gorized as mild, 12 were moderate, 10 were severe,
and 3 were very severe.
The SHIP cohort matched 134 healthy controls.
CPX RESULTS AND ASSOCIATIONS WITH EXERCISE
CAPACITY. Unadjusted peak VO2 was similar between
the 2 principal groups (COPD 17.1  4.6 ml/min/kg and
HFrEF 16.4  3.6 ml/min/kg, p ¼ 0.48). Table 2 gives
the adjusted mean values for all CPX variables within
each group. 8 patients in the COPD group, 1 in the
HFrEF group, 1 in the mixed group, and 2 healthy
controls, did not achieve AT and were excluded from
analyses on AT dependent variables only.
Among the patients, peak VO2 correlated with
estimated glomerular ﬁltration rate (r ¼ 0.30, p ¼
0.003) and Log10BNP (r ¼ –0.35, p ¼ 0.001) but not
with hemoglobin or sodium. Fourteen individuals
had atrial ﬁbrillation or ﬂutter but there was no sig-
niﬁcant difference in peak VO2 compared to sinus
rhythm (p ¼ 0.24).
ASSOCIATIONS BETWEEN SPIROMETRY AND CPX IN
HFrEF. On multivariate regression analysis peak
VO2 did not relate to FEV1 in patients with HFrEF
(p ¼ 0.20). Only breathing reserve at AT (p ¼ 0.03)
and peak (p ¼ 0.01), and peak minute ventilation
(p ¼ 0.04) related to FEV1, while only O2-pulse related
to KCO(Hb) with borderline signiﬁcance (p ¼ 0.047).
DIFFERENCES IN VARIABLES BETWEEN GROUPS. A
comparison of results across groups is shown in
Table 2, and between the 2 disease groups in Figure 1.
All measures of peak VO2, the AT, the VE/VCO2-slope
and ratio at AT, end-tidal CO2, and circulatory power
all showed signiﬁcant differences between healthy
controls and each disease group, but not between the
disease groups. OUES, OUES/kg, and percent pre-
dicted OUES differed signiﬁcantly between COPD and
HFrEF, and between HFrEF and healthy controls.
OUES also differed between COPD and healthy con-
trols but not when corrected for weight or percent
predicted. The unadjusted O2-pulse differed betweenall groups, and was signiﬁcantly higher in the HFrEF
than the COPD group but the 2 disease states did not
differ as percent predicted. Double product differed
between all groups, with lowest values in the HFrEF
group, and highest in healthy controls. Breathing
reserve at the AT was signiﬁcantly lower in the COPD
compared to the HFrEF group and at peak was
signiﬁcantly lower in the COPD compared with both
other groups. VO2 to work-rate relationship was
signiﬁcantly lower in patients with HFrEF compared
to the other groups. OUEP was signiﬁcantly lower in
the COPD compared to the HFrEF group.
RECEIVER-OPERATINGCHARACTERISTICCURVEANALYSIS
AND RECLASSIFICATION INDICES. Table 3 shows com-
parisons of the discriminant abilities of the variables,
quantiﬁed as AUCs. Variables with good discrimina-
tion between COPD and HFrEF were breathing
FIGURE 1 Dotplots for 9 CPX Variables in Patients With COPD and HFrEF
Dotplots for 9 cardiopulmonary exercise testing variables in patients with chronic obstructive pulmonary disease (COPD) and heart failure with
reduced ejection fraction (HFrEF). Each dot represents an individual with mean values represented by black lines. AT ¼ anaerobic threshold;
BR ¼ breathing rate; VO2 ¼ oxygen uptake; VO2:WR slope ¼ oxygen-uptake to work-rate relationship.
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256reserve (AUC: 0.91), breathing reserve at AT (AUC:
0.89), OUES/kg (AUC: 0.84), and percent predicted
OUES (AUC: 0.87); none of these AUC values differed
signiﬁcantly. Double product and O2 pulse were
moderate discriminators but not signiﬁcantly
different from breathing reserve (the discriminator
with the greatest AUC) after a Bonferroni correction.
Other variables were either signiﬁcantly worse dis-
criminators or did not discriminate at all.
Variables with good discrimination between COPD
and healthy controls were breathing reserve, peak
VO2, VE/VCO2 at AT, O2-pulse, and circulatory power.
Variables with good discrimination between HFrEF
and healthy controls were OUES, double product,
peak VO2, circulatory power, VE/VCO2 slope, and VO2
at AT.
Including patients with mixed disease under their
primary diagnosis worsened discrimination margin-
ally (Online Table 1).To ensure that patients not achieving AT were not
inﬂuencing its power to detect a difference in groups,
peak VO2 was substituted for the AT in these patients.
The AUC for the VO2 at AT in ml/min was 0.60 and
0.57 as percent predicted peak VO2, both similar to
the values seen when those not achieving the AT
were excluded.
BNP measurements were obtained in 55 of 65 pa-
tients and showed an AUC of 0.91, which was not
signiﬁcantly different from BR or percent predicted
OUES (Figure 2). The addition of BNP to a logistic
model including percent predicted OUES improved
the AUC nonsigniﬁcantly from 0.90 to 0.95 (p ¼ 0.07).
The further addition of BR again nonsigniﬁcantly
increased the AUC to 0.98 (p ¼ 0.10).
Optimal cutoffs were identiﬁed for percent pre-
dicted OUES and BR. A threshold of 89.2% predicted
OUES showed sensitivity of 80% and speciﬁcity of
85% to predict HFrEF, correctly classifying 54 of 65
TABLE 3 AUC for a Number of CPX Variables
HFrEF Versus COPD
(Excluding Mixed)
HFrEF Versus
Healthy Adults
COPD Versus
Healthy Adults
BR, % 0.91 (0.84–0.98) 0.58 (0.49–0.68) 0.96 (0.94–0.99)
Breathing reserve at AT, % 0.89 (0.80–0.98) — —
OUES, % predicted 0.87 (0.79–0.96) 0.89 (0.82–0.95) 0.52 (0.39–0.66)
OUES/kg 0.84 (0.75–0.93) 0.89 (0.84–0.95) 0.59 (0.45–0.72)
O2 pulse, ml/beat 0.80 (0.69–0.91) 0.61 (0.51–0.71) 0.89 (0.84–0.95)
Peak oxygen saturations, % 0.79 (0.68–0.90) — —
DP, mm Hg beats/min 0.78 (0.67–0.90) 0.91 (0.86–0.95) 0.75 (0.65–0.84)
RER at peak 0.75 (0.62–0.88) — —
VO2/WR slope 0.68 (0.54–0.83) 0.70 (0.60–0.81) 0.52 (0.38–0.66)
HR at peak, beats/min 0.68 (0.55–0.81) 0.80 (0.73–0.88) 0.70 (0.60–0.80)
Peak VO2, ml/min 0.66 (0.52–0.79) 0.82 (0.75–0.88) 0.90 (0.84–0.95)
OUEP 0.65 (0.51–0.80) — —
OUES 0.65 (0.51–0.78) 0.83 (0.76–0.90) 0.71 (0.60–0.83)
AT, ml/min 0.65 (0.49–0.80) 0.67 (0.58–0.76) 0.79 (0.69–0.89)
VE/VCO2 slope 2 0.64 (0.48–0.79) — —
HR/VO2 slope 0.63 (0.49–0.77) 0.50 (0.39–0.62) 0.65 (0.54–0.76)
VE/VCO2 ratio AT 0.59 (0.42–0.77) 0.85 (0.79–0.91) 0.88 (0.80–0.97)
VE/VCO2 slope 1 0.57 (0.42–0.73) 0.92 (0.88–0.96) 0.77 (0.65–0.90)
AT, % of predicted peak VO2 0.56 (0.40–0.72) 0.72 (0.62–0.82) 0.68 (0.54–0.83)
O2 pulse, % predicted 0.56 (0.41–0.71) 0.79 (0.70–0.88) 0.82 (0.72–0.92)
VE/VCO2 ratio nadir 0.54 (0.38–0.70) — —
Peak VO2, ml/min/kg 0.54 (0.38–0.69) 0.89 (0.83–0.94) 0.83 (0.74–0.91)
Circ power, mm Hg ml/min 0.53 (0.37–0.68) 0.90 (0.86–0.95) 0.88 (0.81–0.94)
Peak VO2, % predicted 0.51 (0.36–0.66) 0.91 (0.86–0.96) 0.90 (0.82–0.98)
PETCO2 at AT, mm Hg 0.51 (0.32–0.69) 0.73 (0.64–0.82) 0.71 (0.58–0.85)
Values are area under the curve (AUC) calculated following 3 receiver-operating characteristic curve analyses: the
primary analysis was patients with heart failure versus patients with COPD (excluding mixed disease); patients with
heart failure versus healthy matched controls from the SHIP cohort; and patients with COPD versus healthy matched
controls from the SHIP (Study of Health In Pomerania) cohort. The AUC does not indicate the direction of the
discrimination. The variables are ordered by the AUC for the primary analysis and grouped as good (AUC: >0.8, top 4
variables), moderate (AUC: >0.70, next 4 variables), and poor discrimination (AUC: #0.70, remaining variables).
Abbreviations as in Tables 1 and 2.
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257patients without mixed disease. A threshold of 33.6%
for BR showed sensitivity of 80% and speciﬁcity of
100% to predict respiratory disease, correctly classi-
fying 56 of 65 patients without mixed disease.
Using a previously determined algorithm (5) that
used the cutoffs for AT of 40% predicted peak VO2,
and BR of 30%, 26 of 65 patients were correctly clas-
siﬁed. Net reclassiﬁcation improvement for percent
predicted OUES over AT showed an improvement of
74.0% (p < 0.001), with an integrated discrimination
improvement of 29.6% (p < 0.001).
DISCUSSION
Among CPX variables OUES and breathing reserve
displayed the greatest ability to discriminate between
HFrEF and COPD, and were the only CPX discrimi-
nators with AUC >0.8. This discriminant ability was
similar to that seen with BNP. OUES also strongly
discriminated HFrEF from healthy adults, while BR
discriminated COPD from healthy adults.
A potential algorithm to help distinguish patients
based on these variables is shown in Figure 3.
Peak VO2, the most widely known CPX variable,
had no capacity to discriminate between cardiac and
pulmonary causes of exercise limitation (AUC:
w0.50); both diseases depressed peak VO2. Impor-
tantly this similarity of peak VO2 between our 2
principal groups allowed us to compare the ability of
other measures to discriminate between cardiac and
lung disease without concerns that observed differ-
ences merely related to differences in peak VO2.
OUES, BR, and VO2 at AT are described individually
in detail subsequently. Select other variables are
described now brieﬂy.
VO2/WR slope had signiﬁcantly lower values in
patients with HFrEF but was only moderately
discriminant, while in COPD it behaved similarly to
healthy adults. A previous study showing lower
slopes in cardiovascular disease compared with
healthy controls (15) had shorter exercise times
among the patients, which may inﬂuence its value
(16). In our current study individualized protocols
resulted in similar, and recommended, exercise times
(1), suggesting that cardiovascular limitation may
lower the slope even with optimal exercise duration.
The O2-pulse, a surrogate for stroke volume, was
unexpectedly higher in HFrEF, compared to COPD,
although this difference was not seen when corrected
using predictive equations. We believe that high
beta-blockade use within the HFrEF group led to
lower heart rates, greater ﬁlling times, and therefore
higher stroke volumes. Second, the O2-pulse
is dependent on arteriovenous oxygen contentdifference, often reduced in COPD patients with
lower arterial saturations and higher peak venous
saturations. The predicted O2-pulse was unsurpris-
ingly signiﬁcantly higher in healthy controls
compared to both disease groups.
All measurements of the VE/VCO2 relationship
failed to discriminate the disease groups, but were
signiﬁcantly higher than healthy controls. In patients
with HFrEF they are abnormal due to hyperventila-
tion and perfusion to ventilation mismatching (17). In
COPD a number of causes lead to an abnormal VE/
VCO2 relationship including mismatching of ventila-
tion to perfusion.
OXYGEN UPTAKE EFFICIENCY SLOPE. The OUES,
largely effort independent, is calculated as the slope
of the semilog relationship between O2 and minute
ventilation (18). OUES appears to be unaffected by
COPD. Our group has previously found, within a large
retrospective heart failure cohort, that patients with
FIGURE 2 Comparison of the Area Under the ROC Curve for BNP and Percent
Predicted OUES
BNP ¼ B-type natriuretic peptide; OUES ¼ oxygen uptake efﬁciency slope; ROC ¼ receiver-
operating characteristic.
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258low percent predicted FEV1 have lower peak VO2 but
not OUES (19). In the current study OUES did not
relate to FEV1 or KCO(Hb).
OUES was signiﬁcantly lower in HFrEF than COPD,
despite similar exercise capacities, and healthy con-
trols, and on ROC curve analysis OUES, when weight
adjusted or as a percent predicted, was a good diag-
nostic indicator of HFrEF with similar power to
discriminate these 2 common causes of breathless-
ness as BNP. Importantly, OUES, when corrected,
appears unaffected by COPD. Given the small
numbers of patients within the mixed group further
evaluation of the role of the OUES in patients with
mixed disease would be beneﬁcial.
Why did OUES differ? Patients with heart failure
typically have an abnormal peak VO2 but may still
ventilate to high levels. A considerable portion of
exercise occurs where the VE and VO2 relationships
are decoupled because of anaerobic metabolism and
hyperventilation. This results in increasing levels of
alveolar pO2, worse ventilatory efﬁciency towards
peak exercise, and a “ﬂattened” relationship (19–21).
In contrast COPD patients behave similar to healthy
adults failing to progress to maximal exercise, and are
less anerobic at peak exercise. Furthermore, due to
the increasing ventilatory constraint during exercise
the increase in alveolar pO2 as a result of anaerobic
metabolism is less pronounced, and alveolar pO2
may actually fall toward peak, thereby rendering
ventilation more efﬁcient (22), offsetting inefﬁcient
mechanisms such as ventilation:perfusion mismatch.Therefore, the VO2/log10VE curve may be “shifted”
rightward (higher log10VE for any given VO2) but the
curve’s gradient itself is unchanged. This hypothesis
may also explain why our mixed cohort had OUES
values close to predicted.
BREATHING RESERVE. Breathing reserve has long
been suggested as a discriminator of respiratory limi-
tation (3–5,8). BR at AT has been proposed to reduce
the inﬂuence of voluntarily cessation of exercise (8).
Both BR at AT and peak showed good discriminatory
power. However 32% of our COPD patients did not
achieve AT, similar to the study advocating the BR at
AT (40%), limiting its widespread applicability. In
contrast BR at peak and the OUES aremeasurable in all.
The BR at peak is useful in identifying the principal
physiology limiting exercise. However, unlike OUES,
the magnitude is unlikely to be useful when
measuring disease severity, so its role in serial studies
in 1 patient may be limited.
BR is low in COPD because although in both HFrEF
and COPD peak minute ventilation is reduced, in
COPD patients the maximum voluntary ventilation
(MVV, a function of FEV1) is typically much lower,
leading to a smaller gap between peak minute venti-
lation and MVV; the BR. Patients with mixed disease
had low BR values suggesting this variable may not be
able to distinguish between those with COPD alone or
those with mixed disease.
ANAEROBIC THRESHOLD. In previous CPX algo-
rithms a reduced AT would identify heart failure
(4,5), yet evidence supporting its role is scarce. In
HFrEF VO2 at AT is reduced (23) and superior to peak
VO2 at predicting prognosis (24). Nery et al. (7),
showed VO2 at AT in patients with mitral valve dis-
ease was lower than patients with COPD and healthy
controls; however the numbers were small with sig-
niﬁcant differences in gender and age between
groups. These studies are the foundation of what has
become a ﬁrmly held belief—namely that VO2 at AT
reﬂects cardiac function. Very few CPX studies per-
formed on patients with COPD report the VO2 at AT
however Medoff et al. (8) found no difference be-
tween COPD and heart failure patients with similar
exercise capacities, consistent with our ﬁndings. We
showed that VO2 at AT (as a percent predicted peak
VO2) has poor discriminant ability between the dis-
ease groups, and only showed moderate discrimina-
tion between healthy adults and the 2 groups. We
suggest that this variable is critically determined by
muscle function and any chronic process that impairs
muscular function will reduce the AT.
There may be a concern that the number of pa-
tients without a measured AT inﬂuenced our results.
FIGURE 3 Proposed Algorithm for the Identiﬁcation of Respiratory or Cardiac Disease in a Patient With Exercise Limitation
Breathing reserve (%) is calculated as 100 (maximum voluntary ventilation [MVV] – peak minute ventilation)/MVV, where MVV was calculated
as: 40 $ FEV1 at rest. The percent predicted oxygen uptake efﬁciency slope (OUES) was calculated using data from Barron et al. (14). COPD ¼
chronic obstructive pulmonary disease; VO2 ¼ oxygen uptake.
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259Our results are similar to other studies in terms of
numbers of COPD patients failing to achieve AT (8),
and we believe representative of patients. In all cases
we believe AT had not been achieved rather than
being unidentiﬁable. The failure to attain AT (9 of 29
COPD patients compared with 1 of 44 HFrEF patients)
would appear to display good speciﬁcity, but poor
sensitivity, to diagnose COPD over HFrEF. The sub-
stitution of peak VO2 for the VO2 at AT in patients
failing to achieve AT allowed for all patients to be
involved in the analysis of the AT variables but did
not signiﬁcantly change the ROC results.
STUDY LIMITATIONS. Some of the patients within
the study population were not as symptomatic as
expected, with 16% achieving 85% predicted peak
VO2. We hope to inspire future studies addressing
more severely affected patients, for example thoseawaiting heart or lung transplant. We also made
an assumption that principal pathophysiology was
limiting exercise capacity. It is possible that patients
were limited by musculoskeletal problems or
adiposity. However, this should attenuate between-
group differences.
Prevalence of mixed disease was lower than
anticipated—only 9% of HFrEF and 14% of COPD pa-
tients. Consequently it was not feasible to analyze
mixed disease as a separate group. We performed
sensitivity analyses by comparing inclusion with
exclusion of these individuals and found it had min-
imal effects on estimates of discrimination. However,
future studies including patients with conﬁrmed
coexistent COPD and HFrEF would be valuable.
When comparing the mean values for CPX vari-
ables between the groups, corrections were not made
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
identiﬁcation of markers of heart failure severity help
health care professionals to target appropriate indi-
viduals for optimal disease management including
advanced heart failure therapies such as transplanta-
tion and mechanical circulatory support. CPX testing
already has a central role; here we show which
measured variables are most, and least, affected by
heart failure, and another common condition COPD, to
give physicians greater understanding of the severity
of their patients’ conditions.
TRANSLATIONAL OUTLOOK: Heart failure and
COPD commonly coexist, yet little research has been
done into the exercise physiology of patients with
both conditions. We show how 2 variables, OUES and
BR, are good discriminators of these 2 conditions, and
hope to inspire future researchers to further explore
exercise pathophysiology in patients with coexistent
cardiac and respiratory conditions. We also hope to
promote further research into a potential role for the
OUES in patient selection for advanced heart failure
therapies.
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260for multiple comparisons, and so with large numbers
of statistical comparisons it is possible that some of
the signiﬁcant differences are due to chance. Whilst
comparing AUC values for the primary analysis on
ROC curve analysis Bonferroni corrections were used.
Identiﬁcation of the AT can be challenging; it is
arguable that misidentiﬁcation might have led to its
results. Our protocol was designed for optimal exer-
cise duration, with frequent, small workload in-
creases (2 to 5 W increments every 12 to 20 s), which
should aid identiﬁcation. If despite this, misidentiﬁ-
cation still occurred it is arguably an inherent weak-
ness of the AT, and does not negate our ﬁndings.
Medication use differed between groups, most
importantly beta-blockade. Predictive equations for
O2-pulse and OUES accounted for beta-blocker use, to
minimize between-group differences.
COPD was chosen as the archetypal respiratory,
and HFrEF as the archetypal cardiac diseases. How-
ever the physiological abnormalities differ signiﬁ-
cantly from other respiratory diseases such as
parenchymal lung disease, and other cardiac disease
states such as heart failure with preserved ejection
fraction or valvular disease. Therefore our results
only apply to COPD and HFrEF. Further work would
be needed to show that OUES and BR discriminate a
fuller spectrum of cardiorespiratory disorders.
CONCLUSIONS
OUES and breathing reserve were the best CPX vari-
ables at discriminating HFrEF from COPD, and similar
to BNP. VO2 at AT did not discriminate HFrEF patients
from COPD. In a patient with exercise limitation, BR,
and OUES could be used to identify the principal
pathophysiology.
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